A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
Titel:
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
Auteur:
Ramalingam, S. Goss, G. Rosell, R. Schmid-Bindert, G. Zaric, B. Andric, Z. Bondarenko, I. Komov, D. Ceric, T. Khuri, F. Samarzija, M. Felip, E. Ciuleanu, T. Hirsh, V. Wehler, T. Spicer, J. Salgia, R. Shapiro, G. Sheldon, E. Teofilovici, F. Vukovic, V. Fennell, D.